Circadian Rhythm Sleep Disorder Market Overview
Circadian Rhythm Sleep Disorder Market Size is estimated to reach $915.6 million by 2027. Furthermore, it is poised to grow at a CAGR of 4.3% over the forecast period of 2022-2027. Circadian rhythm disorders, also known as sleep-wake cycle disorders, arise when the body's internal clock, which informs when it's time to sleep or wake, is out of sync with the surroundings. A circadian clock is an internal clock that cycles every 24 hours. Circadian rhythms are 24-hour cycles that run in the background to carry out key tasks and processes as part of the body's internal clock. Most living things, including animals, plants, and bacteria, are affected by these natural processes, which are predominantly affected by light and dark. When a person's sleep-wake cycle is out of sync with their surroundings, they have trouble sleeping and their sleep quality suffers. They have a circadian rhythm if your sleep-wake cycle is disrupted and interferes with your everyday activities. Any alterations in the suprachiasmatic nucleus area led to insomnia or memory loss. Moreover, delayed sleep phase disorder is a circadian rhythm sleep disorder in which the timing of the sleep episode occurs later than desired and is associated with difficulty falling asleep.
The growing prevalence of sedentary lifestyle diseases especially diabetes and the rising aged population are some of the factors driving the Circadian Rhythm Sleep Disorder Market growth during the forecast period 2022-2027.
Circadian Rhythm Sleep Disorder Market Report Coverage
The report: “Circadian Rhythm Sleep Disorder Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Circadian Rhythm Sleep Disorder Market.
- Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of sleep disorders. Asia-Pacific is estimated to offer lucrative growth opportunities to the manufacturers owing to increasing geriatrics, demand for better healthcare facilities as well a boost in the investments done by government and private companies in the pharma industry. The proliferation of sleep disorders is predicted to augment the market growth during the forecast period of 2022-2027.
- The growing prevalence of sleep disorders is estimated to drive the market growth of the Circadian Rhythm Sleep Disorder Market.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Circadian Rhythm Sleep Disorder Market Report.
Circadian Rhythm Sleep Disorder Market based on drugs can be further segmented into Benzodiazepines, Non-Benzodiazepine hypnotics, Orexin receptor antagonists, and Melatonin receptor agonists. Melatonin receptor agonists held a dominant market share in the year 2021 and are estimated to be the fastest-growing, with a CAGR of 5.1% over the forecast period of 2022-2027. Melatonin stimulates a few signaling cascades when it binds to melatonin receptors. Activation of the MT1 receptor inhibits the adenylyl cyclase, which has a rippling effect of non-activation, beginning with decreased cyclic adenosine monophosphate (cAMP) formation and progressing to decreased protein kinase A (PKA) activity, which inhibits the phosphorylation of cAMP-responsive element-binding protein (CREB binding protein) into P-CREB. Melatonin receptor agonists are melatonin analogs that attach to the melatonin receptor and activate it. Agonists of the melatonin receptor are used to treat a variety of conditions, including sleep problems and depression. Ramelteon demonstrated significantly shortened sleep onset latency and increased total duration of sleep. Hence, Melatonin receptor agonist like Ramelteon is dominating the market.
Circadian Rhythm Sleep Disorder Market Segmentation Analysis- By Application
Circadian Rhythm Sleep Disorder Market based on age can be further segmented into Delayed Sleep Phase Disorder, Advanced Sleep Phase Disorder, Jet Lag, Shift Work Disorder, Irregular Sleep-Wake Rhythm, Non-24-hour Sleep-wake Syndrome. The Delayed Sleep Phase Syndrome segment held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 5.5% over the forecast period of 2022-2027 owing to neuron dysfunction in elders, teens, and comorbidities. DSWPD (delayed sleep-wake phase disorder) is a sleep disorder in which a person's sleep is two or more hours later than the socially acceptable or traditional bedtime. This problem of waking up at the desired hour is caused by the delay in falling asleep. Sleep deprivation is a typical complaint among the elderly. Over half of the men and women in a National Institute on Aging study of over 9,000 people aged 65 and up had at least one persistent sleep issue. Sleep issues in the younger generation can manifest themselves in a variety of ways, including trouble falling asleep and staying asleep. According to the National Library of Medicine, the most prevalent circadian rhythm sleep problem is delayed sleep phase disorder, which affects 0.17 percent of the US population and 7–16 percent of teenagers, thereby, driving the segment growth.
Circadian Rhythm Sleep Disorder Market Segmentation Analysis- By Geography
The Circadian Rhythm Sleep Disorder Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 35% in the year 2021 as compared to the other counterparts on account of rising lifestyle change disorders like Obesity, Diabetes, and Hypertension. According to the National Library of Medicine, in 2019, the most prevalent circadian rhythm sleep problem is delayed sleep phase disorder, which affects 0.17 percent of the US population and 7–16 percent of teenagers.
However, Asia-Pacific is estimated to be the fastest-growing, over the forecast period of 2022-2027 on account of rising geriatric people. According to UNFPA, in 2020, the number of elderly people in Asia-Pacific is increasing at an unprecedented rate, and the area is at the forefront of the global population aging crisis. In Asia and the Pacific, one in every four persons will be over 60 years old by 2050. Between 2010 and 2050, the region's population of senior adults (those over 60) will treble, reaching about 1.3 billion individuals.
Circadian Rhythm Sleep Disorder Market Drivers
Growing Prevalence of Sleep Disorders is Boosting the Circadian Rhythm Sleep Disorder Industry growth
According to the American Journal of Medical Chemistry (AJMC), the incidence of narcolepsy has grown by roughly 14%, from 38.9 in 2013 to 44.3 in 2016. From the research period of 2429 to 3240, the prevalence of Obstructive Sleep Apnoea (OSA) increased by 41%. According to AAFP, an estimated 50-70 million persons in the United States suffer from one or more sleep problems. Circadian rhythm sleep disruption is one of the most frequent and underappreciated sleep disorders. When a person's biological clock fails to synchronize to a 24-hour day, the disease develops. Around 7% of urban teenagers suffer from delayed sleep phase disorder. Delayed Sleep Phase Syndrome (DSPS) is a frequent kind of circadian rhythm sleep disorder that affects adolescents and young adults. It is estimated to affect 0.17 percent of the overall population and 7–16 percent of adolescents. This increasing incidence was also seen in other sleep disorders that were studied. It's been estimated that 5-10% of patients in sleep clinics with persistent insomnia have delayed sleep phase disorder. Persons who are blind are more afflicted by the condition than those who are seeing. Circadian rhythm sleep problem affects 55-70 percent of those who are completely blind. Thus, the rising prevalence of sleep disorders is estimated to rise the growth of the market.
Growing FDA Clearances for Sleep Disorders is estimated to be Propelling the Market
Additionally, rising FDA clearance in the United States, announcements of new information or production capabilities, and partnerships by market participants are likely to support the circadian rhythm sleep disorder market growth throughout the forecast period. For example, in December 2020, Vanda Pharmaceutical announced that the US Food and Drug Administration (FDA) had approved its HETLIOZ capsule and liquid formulations for the diagnosis of children and adults with Smith-Magennis Syndrome (SMS), a developmental disorder characterized by sleep disturbances. Furthermore, Eisai reported in October 2018 that they have provided fresh data for the phase II assessment of Lemborexant, an investigational sleep-wake regulation drug, for the identification of irregular sleep-waking rhythm disturbance in Alzheimer's disease patients with mild to moderate dementia. In Barcelona, Spain, evidence on Alzheimer's disease was presented at the 11th Clinical Trials meeting. More than 6 million Americans of all ages have Alzheimer's. An estimated 6.5 million Americans age 65 and older are living with Alzheimer's in 2022. Seventy-three percent are age 75 or older. About 1 in 9 aged 65 and older (10.7%) has Alzheimer's. Lemborexant was created to diagnose a variety of sleep-wake problems, including insomnia. Hence, FDA approvals are likely to boost the market.
Circadian Rhythm Sleep Disorder Market Challenges
Lack of Awareness about Sleep Disorders especially in Developing Countries is estimated to Decline in the Market
According to NCBI 2020, unfortunately, in clinical practice, many of these illnesses can go unnoticed and untreated. Despite the fact that physicians recognize the importance of healthy sleep for patient health, the topic is frequently overlooked in primary care. Sleep problems are also becoming more widely recognized in underdeveloped countries, according to recent studies. According to Healthline 2020, in a nutshell, sleep deprivation is defined as a loss of sleep or a reduction in the quality of sleep over time. Regularly getting fewer than 7 hours of sleep has long-term health repercussions that impact the entire body. When compared to whites, black adults are almost twice as likely to describe sleeping too little and are 60% more likely to report sleeping too much. An underlying sleep issue also is to blame. A person’s body, like oxygen and food, requires sleep to function properly. Your body recovers and restores its chemical equilibrium as you sleep. Your brain helps you remember things by forming new mental connections. A person’s brain and body processes will not work properly if you don't get enough sleep. It can also have a significant negative impact on your quality of life. Hence, lack of awareness is estimated to decrease the Market.
Circadian Rhythm Sleep Disorder Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Circadian Rhythm Sleep Disorder Market. The top 10- Circadian Rhythm Sleep Disorder Market companies are-
- Vanda Pharmaceuticals, Inc
- akeda Pharmaceutical Company Limited
- Idorsia Pharmaceuticals Ltd
- VU University Medical Center
- The Sunbox Company
- Carex Health
- Eisai Co.
- Beurer GmbH
- In January 2022, The US Food and Drug Administration (FDA) authorized QUVIVIQTM (daridorexant) 25 mg and 50 mg, according to Idorsia Ltd. In contrast to therapies that normally sedate the brain, QUVIVIQ is a dual orexin receptor antagonist that prevents the binding of the wake-promoting neuropeptides orexins and is considered to reduce hyperactive wakefulness.
- In January 2020, Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical firm focused on CNS illnesses, announced the opening of Neuraxpharm Austria and the purchase of Easypharm OTC GmbH, a privately-owned Austrian Consumer Healthcare company. Easysleep®, the leading insomnia medication with its unique mix of melatonin, valerian, and hop is at the forefront of the Austrian OTC sleep aid industry, with numerous distinct formulations in the form of pills, spray, and tea. easyrelax® helps to relieve stress, anxiety, and restlessness.
- In December 2019, Eisai Co., a Japanese pharmaceutical company, stated that Dayvigo; an insomnia medication for adult patients had been approved by the US Food and Drug Administration. The FDA authorized Dayvigo in dosages of 5 mg and 10 mg based on two late-stage trials that compared the medicine to a placebo for up to one month and six months in patients with insomnia.
Report Code: HCR 0377
Report Code: HCR 52488
Report Code: HCR 32357
For more Lifesciences and Healthcare Market reports, please click here